{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,16]],"date-time":"2025-06-16T05:44:23Z","timestamp":1750052663783},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,21]]},"DOI":"10.7759\/cureus.62863","type":"journal-article","created":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T02:53:11Z","timestamp":1719024791000},"source":"Crossref","is-referenced-by-count":3,"title":["Isolated Adrenocorticotropic Hormone (ACTH) Deficiency as an Immune-Related Adverse Event Following Combination Immune Checkpoint Inhibitor Therapy"],"prefix":"10.7759","author":[{"given":"Mari","family":"Matsuhiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimitaka","family":"Shibue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Osawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.578802","article-title":"Clinical heterogeneity of acquired idiopathic isolated adrenocorticotropic hormone deficiency","volume":"12","author":"Fujita Y","year":"2021","unstructured":"Fujita Y, Bando H, Iguchi G, et al.. Clinical heterogeneity of acquired idiopathic isolated adrenocorticotropic hormone deficiency. Front Endocrinol (Lausanne). 2021, 12:578802. 10.3389\/fendo.2021.578802","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang LS","year":"2019","unstructured":"Chang LS, Barroso-Sousa R, Tolaney SM, Hodi FS, Kaiser UB, Min L. Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr Rev. 2019, 40:17-65. 10.1210\/er.2018-00006","journal-title":"Endocr Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ19-0163","article-title":"Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society","volume":"66","author":"Arima H","year":"2019","unstructured":"Arima H, Iwama S, Inaba H, et al.. Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: clinical guidelines of the Japan Endocrine Society. Endocr J. 2019, 66:581-6. 10.1507\/endocrj.EJ19-0163","journal-title":"Endocr J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b M","year":"2020","unstructured":"Stelmachowska-Bana\u015b M, Czajka-Oraniec I. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review. Endocr Connect. 2020, 9:R207-28. 10.1530\/EC-20-0342","journal-title":"Endocr Connect"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2016-2300","article-title":"Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab","volume":"101","author":"de Filette J","year":"2016","unstructured":"de Filette J, Jansen Y, Schreuer M, Everaert H, Velkeniers B, Neyns B, Bravenboer B. Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J Clin Endocrinol Metab. 2016, 101:4431-9. 10.1210\/jc.2016-2300","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2016.08.020","article-title":"Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series","volume":"186","author":"Caturegli P","year":"2016","unstructured":"Caturegli P, Di Dalmazi G, Lombardi M, et al.. Hypophysitis secondary to cytotoxic T-lymphocyte-associated protein 4 blockade: insights into pathogenesis from an autopsy series. Am J Pathol. 2016, 186:3225-35. 10.1016\/j.ajpath.2016.08.020","journal-title":"Am J Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.21873\/cdp.10246","article-title":"Hypothyroidism with ACTH deficiency during pembrolizumab therapy for lung cancer: case report and literature review","volume":"3","author":"Hashinokuchi A","year":"2023","unstructured":"Hashinokuchi A, Haro A, Minagawa R, Haruta Y, Kawano H, Suehiro T, Sugimachi K. Hypothyroidism with ACTH deficiency during pembrolizumab therapy for lung cancer: case report and literature review. Cancer Diagn Progn. 2023, 3:498-503. 10.21873\/cdp.10246","journal-title":"Cancer Diagn Progn"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0760","article-title":"Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis","volume":"186","author":"Seejore K","year":"2021","unstructured":"Seejore K, Giannoudi M, Osborn D, et al.. Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis. Eur J Endocrinol. 2021, 186:83-93. 10.1530\/EJE-21-0760","journal-title":"Eur J Endocrinol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231236","article-title":"Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency","volume":"12","author":"Martins Machado C","year":"2019","unstructured":"Martins Machado C, Almeida Santos L, Barroso A, Oliveira MJ. Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency. BMJ Case Rep. 2019, 12:10.1136\/bcr-2019-231236","journal-title":"BMJ Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-021-01141-8","article-title":"Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review","volume":"24","author":"Iglesias P","year":"2021","unstructured":"Iglesias P, S\u00e1nchez JC, D\u00edez JJ. Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review. Pituitary. 2021, 24:630-43. 10.1007\/s11102-021-01141-8","journal-title":"Pituitary"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/254559-isolated-adrenocorticotropic-hormone-acth-deficiency-as-an-immune-related-adverse-event-following-combination-immune-checkpoint-inhibitor-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T02:53:14Z","timestamp":1719024794000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/254559-isolated-adrenocorticotropic-hormone-acth-deficiency-as-an-immune-related-adverse-event-following-combination-immune-checkpoint-inhibitor-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.62863","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6,21]]}}}